Compare
Johnson & Johnson vs Eli Lilly & Co vs Merck & Co., Inc. vs Pfizer Inc
| Latest fiscal year | Johnson & Johnson JNJ | Eli Lilly & Co LLY | Merck & Co., Inc. MRK | Pfizer Inc PFE |
|---|---|---|---|---|
| Year ended | 2025-12-28 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $94.19B | $65.18B | $65.01B | $62.58B |
| Revenue growth (YoY) | +6.0% | +44.7% | +1.3% | -1.6% |
| Gross margin | 67.9% | 83.0% (computed) | 74.8% (computed) | 74.3% (computed) |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | 28.5% | 31.7% | 28.1% | 12.4% |
| Net income | $26.80B | $20.64B | $18.25B | $7.77B |
| EPS (Diluted) | $11.03 | $22.95 | $7.28 | $1.36 |
| Operating cash flow | $24.53B | $16.81B | $16.47B | $11.70B |
| Free cash flow | $19.70B | n/a | $12.36B | $9.07B |
| Cash & equivalents | $19.71B | $7.27B | $14.56B | $1.14B |
| Total assets | $199.21B | $112.48B | $136.87B | $208.16B |
| Total liabilities | $117.67B | n/a | n/a | $121.39B |
| Shareholders' equity | $81.54B | $26.54B | $52.66B | $86.78B |
| Return on year-end equity | 32.9% | 77.8% | 34.7% | 9.0% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Johnson & Johnson | Eli Lilly & Co | Merck & Co., Inc. | Pfizer Inc |
|---|---|---|---|---|
| Latest | $94.19B Ended 2025-12-28 | $65.18B Ended 2025-12-31 | $65.01B Ended 2025-12-31 | $62.58B Ended 2025-12-31 |
| 1 year earlier | $88.82B Ended 2024-12-29 | $45.04B Ended 2024-12-31 | $64.17B Ended 2024-12-31 | $63.63B Ended 2024-12-31 |
| 2 years earlier | $85.16B Ended 2023-12-31 | $34.12B Ended 2023-12-31 | $60.12B Ended 2023-12-31 | $59.55B Ended 2023-12-31 |
| 3 years earlier | $79.99B Ended 2023-01-01 | $28.54B Ended 2022-12-31 | $59.28B Ended 2022-12-31 | $101.17B Ended 2022-12-31 |
| 4 years earlier | $78.74B Ended 2022-01-02 | $28.32B Ended 2021-12-31 | $48.70B Ended 2021-12-31 | $81.29B Ended 2021-12-31 |